The inconsistency suggests the PD-L1 expression may not be the primary factor for the lack of response of patients with EGFR-mutant NSCLC to PD-1/PD-L1 inhibitor therapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.